Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican) and Reduced Dose of Cyclosporine A (Neoral) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic) and Standard Dose of Cyclosporine A (Neoral)

Next Previous
Trial Profile

A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican) and Reduced Dose of Cyclosporine A (Neoral) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic) and Standard Dose of Cyclosporine A (Neoral)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Basiliximab; Corticosteroids; Ganciclovir; Methylprednisolone; Mycophenolic acid; Prednisone; Valganciclovir
  • Indications Cytomegalovirus infections; Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms EVERCMV

    • Most Recent Events

    • 06 Jan 2022 Results published in the American Journal of Transplantation
    • 01 Sep 2021 Primary endpoint (Number of participants without CMV infection and without graft loss in CMV seropositive kidney transplant recipients.) has been met as per results presented at the 20th Congress of the European Society for Organ Transplantation
    • 01 Sep 2021 Results presented at the 20th Congress of the European Society for Organ Transplantation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top